Latest News

STAT Plus: FDA slams Akorn for a laundry list of manufacturing problems that put patients at risk

For all the talk lately about quality control problems with some drugs made in India, one has to look no further than the nation’s medicine chest for an example of egregious manufacturing practices.

In a lengthy and especially stern warning letter, the Food and Drug Administration scolded Akorn (ACRX) — which has faced long-running production issues at several facilities — for a laundry list of poor actions that was found during an inspection of a New Jersey plant last summer. And the issues bolster the concerns cited by Fresenius for backing away from its $4.7 billion acquisition of the troubled company last year.

Continue to STAT Plus to read the full story…

Source link

Related posts

Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference


Medical News Today: Weight loss: Plant-based drug 'switches off' hunger


Medical News Today: What does period blood smell like and why?


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy


COVID-19 (Coronavirus) is a new illness that is having a major effect on all businesses globally LIVE COVID-19 STATISTICS FOR World